PMNs from patients with severe psoriasis display higher surface expression of CD66b and CD11b, and lower expression of CD62L compared to patients with moderate psoriasis and healthy controls (HCs)—an effect that is reversed by biological therapy (12). This evidence concerns the gene ITGAM and psoriasis.